0001557746false00015577462026-11-162026-11-16

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): November 16, 2026

​

​

Aclaris Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

​

​

​

​

​

​

Delaware

​

001-37581

​

46-0571712

(State or other jurisdiction of incorporation)

​

(Commission File Number)

​

(IRS Employer
Identification No.)

​

701 Lee Road, Suite 103

Wayne, PA 19087

(Address of principal executive offices, including zip code)

​

(484) 324-7933

(Registrant’s telephone number, including area code)

​

N/A

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act: 

​

 

 

 

 

 

Title of Each Class:

  ​ ​ ​

Trading Symbol(s)

  ​ ​ ​

Name of Each Exchange on which Registered

Common Stock, $0.00001 par value

 

ACRS

 

The Nasdaq Stock Market, LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 7.01 Regulation FD Disclosure.

​

On November 16, 2026, Aclaris Therapeutics, Inc. (the “Registrant”) issued a press release announcing top line results from its Phase 2 ADMIRATION trial of bosakitug (ATI-045), a humanized anti-thymic stromal lymphopoietin monoclonal antibody, in patients with moderate-to-severe atopic dermatitis (the “Top Line Results”). A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

​

On November 16, 2026, the Registrant also issued a press release announcing the initiation of its randomized, double-blind, placebo-controlled Phase 2b ALPHA trial of modzatinib (ATI-2138), an investigational oral inhibitor of interleukin-2-inducible T cell kinase and Janus kinase 3, in patients with moderate-to-severe lichen planus (the “ALPHA Trial”). A copy of this press release is furnished herewith as Exhibit 99.2 to this Current Report on Form 8-K.

​

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and in Exhibits 99.1 and 99.2 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

​

Item 8.01 Other Events.

​

Top Line Results

​

The Top Line Results announced were as follows:

​

The Phase 2 trial did not achieve the primary endpoint of percent change from baseline in the Eczema Area and Severity Index score at Week 24 or secondary endpoints. Pharmacodynamic (PD) results showed robust target engagement of TSLP and downregulation of biomarkers related to immune activation including Th1, Th2, and Th17. Bosakitug was generally well tolerated in the trial.  

​

ALPHA Trial

​

The Registrant announced that it expects top line results from the oral erosive lichen planus cohort of the ALPHA Trial in the second half of 2027.

​

Other Announcements

​

The Registrant also announced the following:

​

The Registrant has completed IND-enabling studies for ATI-9494, its ITK/TXK inhibitor, and expects to file the IND in the fourth quarter of 2026. The planned Phase 1 clinical program will evaluate single (SAD) and multiple ascending doses (MAD) of ATI-9494 followed by a proof-of-concept portion in an undisclosed indication. The Registrant expects to initiate the trial in the first quarter of 2027.  

​

The Registrant intends to initiate a Phase 2b trial of ATI-052, its anti-TSLP/IL-4Rα bispecific antibody, in eosinophilic esophagitis in the first quarter of 2027.

​

Cautionary Note Regarding Forward-Looking Statements

​

This Current Report on Form 8-K, including Exhibits 99.1 and 99.2 hereto, contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on the Registrant’s current beliefs and expectations. These forward-looking statements include expectations regarding the Registrant’s development plans and expected milestones for modzatinib, ATI-052 and ATI-9494, including the timing of top line results from the oral erosive

2

lichen planus cohort of the ALPHA Trial, the plans for and timing of initiating a Phase 2b trial of ATI-052 in eosinophilic esophagitis, and the plans for and timing of submitting an investigational new drug application for, and initiating a Phase 1 program for, ATI-9494. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, risks associated with interim, top line and preliminary data, including that such data may change as more data become available, the impact of the Top Line Results on the Registrant’s business and its ability to execute on its development strategy, the Registrant’s reliance on third parties over which it may not always have full control, the Registrant’s ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and other risks and uncertainties that are described in the Risk Factors section of the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025 and other filings the Registrant makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “SEC Filings” page of the “Investors” section of the Registrant’s website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this Current Report on Form 8-K and are based on information available to the Registrant as of the date of this Current Report on Form 8-K, and the Registrant assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

​

Item 9.01 Financial Statements and Exhibits.

​

(d) Exhibits

Exhibit

 

Number

Exhibit Description

99.1

​

Press Release (Top Line Results).

99.2

​

Press Release (ALPHA Trial).

104

The cover page from Aclaris Therapeutics, Inc.’s Form 8-K filed on November 16, 2026, formatted in Inline XBRL.

​

​

​

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

​

ACLARIS THERAPEUTICS, INC.

​

​

​

​

By:

/s/ Kevin Balthaser

Date: November 16, 2026

​

Kevin Balthaser

​

​

Chief Financial Officer

​

4